✦ LIBER ✦

Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

✍ Scribed by Chen, Yi-Bin; Li, Shuli; Del Rio, Candice; Coughlin, Erin; Ballen, Karen K.; Cutler, Corey S.; Dey, Bimalangshu R.; Ho, Vincent T.; McAfee, Steven L.; Spitzer, Thomas R.; Alyea, Edwin P.

Book ID: 122305194
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 124 KB
Volume: 20
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2013.12.367

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reduced intensity conditioning (RIC) for

Reduced intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HCT) in patients with AML evolved from MDS or therapy related AML

✍ M.R. O’Donnell; R. Roberto; A.S. Stein; J. Palmer; M. Slovak; R. Nakamura; D.S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Outcomes of patients with AML and MDS wh

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

✍ Pollyea, D A; Artz, A S; Stock, W; Daugherty, C; Godley, L; Odenike, O M; Rich, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 138 KB

Allogeneic Hematopoietic Stem Cell Trans

Allogeneic Hematopoietic Stem Cell Transplantation (SCT) Using Fludarabine/Treosulfan Conditioning Regimen Compared With Busulfan-Based Myeloablative And Reduced-Intensity Conditioning In Patients With AML And MDS; Relative Outcomes Depend On Disease Status At SCT

✍ A. Shimoni; N. Shem-Tov; A. Rand; Y. Volchek; R. Yerushalmi; I. Hardan; A. Nagle 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Allogeneic stem-cell transplantation in

Allogeneic stem-cell transplantation in patients with AML and MDS using myeloablative versus reduced-intensity doses of intravenous busulfan (Busulfex): The role of dose intensity

✍ A. Shimoni; M. Yeshurun; I. Hardan; A. Avigdor; N. Shem-Tove; I. Ben-Bassat; A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Survival Advantage for Patients with AML

Survival Advantage for Patients with AML and MDS Given Allogeneic Hematopoietic STEM CELL Transplantation Using Myeloablative Versus Reduced Intensity Conditioning (RIC) MAY Become Apparent 5-10 YEARS after Transplantation

✍ Shimoni, Avichai; Shem-Tov, Noga; Volchek, Yulia; Danylesko, Ivetta; Yerushalmi, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase II Trial of Busulfan-Based Tandem

Phase II Trial of Busulfan-Based Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed By Reduced Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma

✍ Chen, Yi-Bin; Li, Shuli; Del Rio, Candice; Driscoll, Jessica; Sadrzadeh, Hossein 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 220 KB